Company ProfilePremium

Intelicare Holdings Limited

Company Profile Analysis

Ticker: ICR.AX

ESOMAR 23 Corporate BadgeISO Certifications Badge
Intelicare Holdings Limited - Company showcase

Year Founded & Workforce

2016

Intelicare Holdings Limited logo

Intelicare Holdings Limited Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Intelicare Holdings Limited Overview

InteliCare is a Perth-based software-as-a-service company. It commercialises a proprietary, AI-driven Internet-of-Things care platform for Australian residential aged care, retirement living, disability and health providers. The platform combines ambient sensors, vital-sign and bed-occupancy monitoring, falls detection, real-time location tracking, staff duress and, since 2026, a proprietary nurse call layer, all in one clinical dashboard. Its purpose is to improve resident safety, reduce manual welfare checks and support compliance under Australia's new aged care regulatory regime. After six years of pilots, sub-scale revenue and repeated equity raisings, the company reached its first commercial inflection in FY2026. It signed a five-year, roughly A$8.8 million Master Subscription Agreement with mecwacare covering 22 facilities and about 1,600 beds. It expanded its Hardi Aged Care contract, entered retirement living through Warrigal, more than doubled sales revenue, and recorded its first positive operating cash flow quarter since listing. It remains loss-making, highly concentrated by customer and heavily dilutive.


Company's own description

In its FY2026 Directors' Report, InteliCare describes its principal activities as three items: production of a predictive analytics solution for care providers in aged care, disability and healthcare; sales and marketing; and research and development. ASX announcements in 2026 describe it as an Australian SaaS technology company commercialising its AI-driven InteliCare platform across the aged care, disability and health sectors. The longer boilerplate in its releases says it uses smart sensors and AI on a proprietary IoT platform to help people stay in their own homes for longer, while helping providers deliver better and more efficient care.

The FY2026 report describes the year as a transition from validating pilots to deploying at scale. The company focused on converting pilots into long-term contracts, carrying out deployments with leading aged care providers, building recurring SaaS revenue and improving the platform for larger, cheaper rollouts.

Independent characterisation

InteliCare is in practice a hardware-led, SaaS-tailed solution vendor to institutional aged care operators. Its value proposition has three parts:

  1. Clinical safety. It detects falls, bed exits and changes in vital signs or behaviour patterns, and raises alerts.

  2. Workforce productivity. It replaces manual overnight welfare rounds. In the mecwacare Trescowthick pilot, residents needing three-hourly overnight checks fell from 55 to 4.

  3. Compliance and governance. It automates falls reporting, keeps audit trails and analyses alarm response times, which supports alignment with the new Aged Care Act and the strengthened Aged Care Quality Standards.

The company began in 2020 with a home-monitoring and B2C/B2B home care model. Its products then were InteliCare Home and InteliLiving, funded through Home Care Packages and NDIS plans. Since about 2022–2023 it has pivoted firmly toward residential aged care. The 2026 launch of a proprietary nurse call solution marks a further move. InteliCare is no longer only an analytics overlay. It is starting to compete for, or displace parts of, the core clinical communications layer of an aged care facility. That brings it into direct competition with established nurse call vendors.

Revenue model

Revenue streamDescriptionRecognitionFY2025 (AUD)FY2026 (AUD)FY2026 mix
Hardware sales (incl. bundled implementation)Sensors, hubs, gateways, nurse call hardware, plus implementation services bundled where not distinctPoint in time (on delivery)847,0251,845,02990.4%
Subscription (SaaS)Platform subscription fees per bed, site or residenceOver time109,715196,7999.6%
Professional servicesReferenced in mecwacare contract terms; not separately reported————
Total sales revenue——956,7402,041,828100%

Source: FY2026 Financial Report, Note 5: Other income outside sales revenue consists of the R&D tax incentive refund (A$610,680 in FY2026; A$619,528 in FY2025) and interest income. This income is material: in FY2026 it equalled about 30% of sales revenue.

Commercial contracts are structured as multi-year Master Subscription Agreements. Each facility has its own order form, with up-front hardware and implementation fees followed by recurring SaaS. In the June 2026 quarter, hardware fees made up about 69% of cash receipts (Kalkine summary of the June 2026 Quarter Update). The share of recurring revenue is still small, but it is growing: SaaS revenue rose 79.4% year on year in FY2026.

Value chain position, customer types and end-markets

End-marketStatusNamed customers / counterparties
Residential aged care (RAC)Core market; most revenue in FY2025–FY2026mecwacare (VIC), Hardi Aged Care (NSW)
Retirement livingEntered FY2026 (first commercial deployment)Warrigal Care (NSW/ACT)
Regional / public healthOngoing subscriptionWA Country Health Service (WACHS), Koolberrin Lodge, Narembeen
Home care / disabilityOriginal market (2020–2022); now secondaryHistorical: WA Department of Communities, Swan Care, Echo Community Services, Like Our Own
Hospital / remote patient monitoringPilot stagePeter MacCallum Cancer Centre pilot (concluded early 2024)

InteliCare designs the software, analytics and AI layer and specifies the sensor and hardware stack. Hardware is purchased and resold; hardware expense was A$882,227 in FY2026. Manufacturing arrangements are not publicly disclosed. The company handles implementation itself.

All FY2026 external revenue came from sales to Australian aged care providers (FY2026 Financial Report, Note 4).

Strategy

Stated strategy (themes from the FY2026 annual results and the 21 April 2026 investor presentation)

The company's stated themes, paraphrased:

  1. Convert pilots into long-term contracts. Trescowthick became the mecwacare MSA; the WACHS proof of concept became an ongoing subscription.

  2. Scale deployments with anchor customers. Complete the mecwacare (22 facilities), Hardi (6 facilities plus nurse call) and Warrigal rollouts.

  3. Grow recurring SaaS revenue as installed beds come online.

  4. Improve deployment economics. Zero-touch sensor setup, LiDAR-assisted installation and automated calibration.

  5. Expand across the continuum of care. Residential aged care, retirement living, and potentially home care and new service models (named as a joint innovation area with mecwacare).

  6. Regulatory alignment. Position the platform as supporting compliance with the new Aged Care Act and the strengthened Aged Care Quality Standards.

Management described the company as being at a "commercial inflexion point" in the June 2026 quarter update.

Strategic initiatives in the last 24 months

InitiativeDateDetailStatus
mecwacare five-year strategic partnershipMar 2026MSA plus collaboration on innovation, data-driven care insights, knowledge exchange and at-home care applicationsRolling out (4 sites live; 10 targeted by Dec 2026)
Proprietary nurse call launchFY2026Built from mecwacare's preference for a single platform; can replace legacy nurse call functionsLive at 2 Hardi sites; installing at 2 more
Retirement living entryApr 2026Warrigal: 65 villas; pathway to 10 villagesImplementation
Hardi expansionJul 2026+84 beds at Blacktown; nurse call across 6 sitesUnderway
Product automation programFY2026Zero-touch sensors, LiDAR installer app, GenAI event summariesDelivered
Capital structure simplificationSep 2025Convertible note facility terminatedCompleted
Leadership upgradeMar 2026CEO with multinational health technology backgroundCompleted

Medium-term targets and guidance

TargetHorizonSource
10 mecwacare sites liveEnd of calendar 2026June 2026 Quarter Update; FY2026 Directors' Report
Remaining 2 Hardi facilities deployedEnd of calendar 2026FY2026 Directors' Report
mecwacare full rollout (22 facilities)FY2026–FY2028FY2026 Directors' Report
700 / 2,000 / 4,000 contracted revenue-generating beds30 Jun 2027 / 2028 / 2029CEO performance rights hurdles (FY2026 Remuneration Report)
Revenue, EBITDA or profit guidanceNone issued—

ESG or sustainability commitments: none disclosed. Formal cost reduction programs: none disclosed, although FY2023 reporting highlighted reductions in monthly cash burn.

Products & Services

All products sit within the single reported segment. They are listed individually below.

Sources: FY2026 Directors' Report (Technology and product development); Morningstar profile; startupnews.com.au (May 2020); The Weekly Source (May 2020); StockWireX (March 2026); ASX Hardi announcement (28 July 2026); Stockhead (2022).

Flagship offering. The integrated "analytics, IoT, alerts, sensors and nurse call" bundle being deployed across mecwacare under the five-year MSA.

Pricing disclosure. Per-bed or per-site pricing is not publicly disclosed. Contract-level economics are disclosed for three customers:

Derived aggregate disclosed TCV: about A$12.3M.

Product Portfolio

#Product / moduleDescription and capabilitiesTarget customerLaunch / latest versionPricing model
1

InteliCare Platform (core)

Proprietary AI and predictive analytics IoT platform. It ingests sensor, vital-sign, bed, location and alarm data and issues alerts and insights

RAC, retirement living, disability, health

Commercial since 2020; enhanced continuously through FY2026

Hardware plus implementation plus recurring SaaS per facility order form

2

InteliLiving

Original core app for families and carers giving a real-time view of wellbeing in independent living; listed on Microsoft Azure Marketplace

Seniors and people with disability at home; home care providers

2,020

Monthly subscription, fundable via HCP or NDIS (2020 model)

3

InteliCare Home

Smart-sensor package that learns occupants' normal behaviour without cameras and alerts carers to anomalies

Consumers / home care

2,020

Hardware plus subscription

4

InteliCare Pro

Multi-client interface for residential aged care operators

RAC operators

2,020—
5

InteliCare Hub

Gateway or hub device that connects the sensors

All segments

—

Hardware sale

6

Smart sensors

Ambient motion and environmental sensors, bed occupancy sensors, vital-sign sensing; auto-detection and zero-touch setup added in FY2026

All segments

Ongoing; zero-touch configuration FY2026

Hardware sale

7

Duress pendants (optional)

Wearable personal alarms

Residents and staff

—

Hardware sale

8

Falls detection and end-to-end falls management

Falls detection (100% accuracy, no missed or false falls during the Trescowthick evaluation), event classification, reassignment, manual event creation, automated falls reporting

RAC

Enhanced FY2026

Included in SaaS

9

Vital signs and bed occupancy monitoring

Real-time overnight monitoring that replaces three-hourly welfare checks

RAC

FY2025–FY2026

Included in SaaS

10

InteliCare Nurse Call (proprietary)

Nurse call display and management; can integrate with or replace legacy nurse call functions. Developed at mecwacare's request for a single unified platform

RAC operators

2026 (live at Hardi Manly Vale and Blacktown; installing at Wyoming and Seven Hills)

Separate fees (part of the A$371k Hardi uplift)

11

Staff CONNECT app

Mobile app for care staff: real-time alarm visibility, location search for residents, staff and equipment, proximity-based alarm closure

Care staff

FY2026

Included in SaaS

12

Facility Manager Dashboard

Single real-time view of resident and facility data combining falls, vitals, bed exit, duress and nurse call

Facility managers

FY2026

Included in SaaS

13

Alarm analytics

Call volumes and response times by shift and across 24-hour cycles

Management, quality and compliance

FY2026

Included in SaaS

14

Real-time location system (RTLS)

Live location tracking of equipment, staff and residents; asset management

RAC

Improved FY2026

Included in SaaS

15

Annunciator application

Configurable alarm annunciation display

RAC

FY2026

Included in SaaS

16

LiDAR installer application

Uses LiDAR to automate spatial data collection and optimise sensor placement, lowering deployment cost

Internal and installers

FY2026

Internal tool

17

Generative AI event summaries

Better event-confidence categorisation feeding GenAI analysis and event summaries

Clinical and management staff

FY2026

Included in SaaS

18

Wearables integration

Integration with a wide range of consumer smart-health wearables

Home care

FY2022

—
19

Implementation and professional services

Site survey, installation, configuration, integration with existing nurse call and care management systems

All contracted customers

Ongoing

Implementation fees and professional services under MSAs

“—” = not publicly disclosed.

ContractTermEstimated TCV (AUD)Composition

mecwacare (MECWA Limited)

5 years (signed Mar 2026; rollout FY2026–FY2028)

~8,800,000

Hardware, implementation, recurring SaaS, professional services across 22 facilities (~1,600 residents)

Hardi Aged Care (initial)

3 years (from 2024)

~2,900,000

~A$1.7M hardware and implementation; ~A$400k per year SaaS at full deployment across 6 facilities

Hardi expansion

Added Jul 2026

~371,000 (initial)

Blacktown +84 beds; nurse call at Blacktown and Manly Vale; four more nurse call sites to be invoiced

Warrigal Care

3 years plus annual renewals

~200,000

Hardware, implementation, SaaS for 65 villas; about A$152k described as annual SaaS subscription payments in the June quarter update

WACHS (Koolberrin Lodge)

2 years plus three 1-year options

—

Ongoing subscription after a two-year proof of concept

“—” = not publicly disclosed.

Financial Narrative

Income statement (five years)

Sources: FY2026 Remuneration Report five-year summary (sales revenue, EBITDA, loss, basic EPS); FY2026 Note 9 (diluted EPS equals basic because the company is loss-making). FY2022 growth of 18% is from the FY2022 Annual Report letter. Other growth and margin figures are derived. Four-year sales revenue CAGR FY2022–FY2026: about 47.6% (derived).

Detailed P&L (two years)

Source: FY2026 Statement of Profit or Loss. The company does not report gross profit or operating income; the derived lines are this analyst's calculations. EBIT equals loss before tax plus finance costs, and includes R&D grant income.

Commentary.

The defining inflection of FY2026 is that sales revenue more than doubled while cash operating costs (excluding hardware cost of goods and share-based payments) stayed broadly flat. Staff costs fell 7.1%. Consultant and administrative costs rose 28.6% and 12.8% respectively. The derived gross margin narrowed slightly, from 59.7% to 56.8%, as the mix shifted toward hardware-heavy initial deployments.

The underlying EBITDA loss improved by A$220,727. The headline net loss improved by only A$146,447 (6.5%), held back by two items. First, share-based payment expense rose about 3.7 times as the board and new CEO received performance rights. Second, finance costs rose about 80% because of the 15% interest rate on the R&D-secured loan.

The long-run trend shows operating discipline. The EBITDA loss has more than halved from A$3.78M in FY2022 to A$1.84M in FY2026, while sales revenue rose 4.75 times. FY2023 and FY2024, however, show the danger in this business model: revenue fell while the company waited for pilots to convert into contracts.

Other income, almost entirely the refundable R&D tax offset, is a structural support to the P&L. It has fallen gradually: about A$1.09M for the FY2022 claim, A$926k for FY2023, A$620k for FY2024 and A$611k for FY2025.

Balance sheet

Sources: FY2026 Financial Report (balance sheet, statement of changes in equity, Note 10 financing reconciliation). FY2024 figures are opening balances at 1 July 2024. FY2022–FY2023 balance sheet data were not available in the reviewed sources and are therefore not shown.

Short-term vs long-term debt: all borrowings are current. The R&D offset advance (A$461,538) carries 15% interest. Insurance premium funding is A$36,102. No long-term debt. No goodwill or capitalised intangibles; all development is expensed. The Appendix 4E reports NTA per share of 0.17 cents for the current period and (0.17) for the prior period.

Commentary. The balance sheet was repaired in FY2026. Net liabilities of A$833k became net assets of A$1.23M, and cash rose more than six-fold to A$2.73M. This was driven by about A$4.05M of gross equity raised (September 2025 and May 2026 placements), not by internally generated cash. Accumulated losses since inception now stand at A$20.99M against A$18.97M of paid-in capital. Contract liabilities of A$682k (payments received in advance) are a modest positive sign of customer prepayment. The company has no capitalised development costs, which makes its asset base conservative.

Cash flow

Source: FY2026 Statement of Cash Flows. FCF = operating cash flow minus capex (derived).

Quarterly inflection. In the June 2026 quarter, customer receipts were A$1.806M out of a full-year total of A$2.121M, which implies only about A$315k in the first nine months. Net operating cash flow was +A$384k, the first positive quarter since the 2020 listing. Roughly A$1.5M of receipts came from mecwacare, and hardware made up about 69% of receipts. The company drew its A$400k R&D facility in full and ended the quarter with A$2.73M in cash (June 2026 Appendix 4C; Kalkine summaries).

Assessment. The positive quarter was driven by up-front hardware billings on a burst of mecwacare deployments, not by recurring revenue covering fixed costs. Sustaining positive cash flow depends on keeping deployment pace up (mecwacare targets 10 live sites by December 2026) until SaaS fees build up enough to cover the cost base, which is roughly A$3.8M a year in supplier and employee payments.

Ratios

All ratios are this analyst's calculations from FY2026 Financial Report data. For this issuer, standard profitability ratios are not meaningful (n/m).

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Revenue by Segment (AUD) and Segment Margins & Growth (%)

MetricFY2024FY2025FY2026

Segment sales revenue (AUD)

280,292956,7402,041,828

Segment result: loss before tax (AUD)

-2,259,315-2,244,263-2,097,816

Segment EBITDA (AUD)

-2,094,265-2,065,657-1,844,930

YoY sales revenue growth (%)

-30.7241.3113.4

Contribution to total revenue (%)

100100100

EBITDA margin (%)

-747.2-215.9-90.4

Revenue type

Revenue typeFY2025FY2026

Hardware sales (AUD)

847,0251,845,029

Subscription / SaaS (AUD)

109,715196,799

Total sales revenue (AUD)

956,7402,041,828

SaaS share of sales revenue (%)

11.59.6

Revenue by Segment (AUD)

MetricH1 FY2026H2 FY2026

Sales revenue (AUD)

489,7071,552,121

Income Statement (AUD) and Margin Analysis (%)

MetricFY2022FY2023FY2024FY2025FY2026

Sales revenue (AUD)

429,845404,345280,292956,7402,041,828

Sales revenue growth (%)

18-5.9-30.7241.3113.4

EBITDA (AUD)

-3,775,617-2,892,387-2,094,265-2,065,657-1,844,930

Net loss after tax (AUD)

-3,932,938-2,998,160-2,259,315-2,244,263-2,097,816

Basic EPS (AUD cents)

-3.80-1.80-1.00-0.49-0.35

Diluted EPS (AUD cents)

-3.80-1.80-1.00-0.49-0.35

Dividends per share (AUD cents)

00000

EBITDA margin (%)

-878.4-715.3-747.2-215.9-90.4

Net margin (%)

-915.0-741.5-806.1-234.6-102.7

Income Statement (AUD) and Margin Analysis (%) (FY2025–FY2026)

Line itemFY2025FY2026

Sales revenue (AUD)

956,7402,041,828

Other income incl. R&D grants and interest (AUD)

627,374619,355

Total revenue and income (AUD)

1,584,1142,661,183

Hardware expense (AUD)

-385,173-882,227

Derived gross profit: sales minus hardware expense (AUD)

571,5671,159,601

Derived gross margin (%)

59.756.8

Development expense (AUD)

-310,530-297,791

Marketing and advertising (AUD)

-7,622-34,042

Staff expense (AUD)

-1,660,699-1,543,224

Consultants (AUD)

-397,077-510,535

Administrative (AUD)

-797,919-900,344

Share-based payments (AUD)

-90,751-337,950

Depreciation and amortisation (AUD)

-94,377-101,589

Derived operating result / EBIT (AUD)

-2,160,034-1,946,519

Finance costs (AUD)

-84,229-151,297

Loss before tax (AUD)

-2,244,263-2,097,816

Income tax (AUD)

00

Balance Sheet (AUD)

MetricFY2024FY2025FY2026

Cash and cash equivalents (AUD)

834,198410,5322,727,755

Borrowings, all current (AUD)

591,759615,236497,640

Lease liabilities (AUD)

20,630101,38227,182

Total debt incl. leases (AUD)

612,389716,618524,822

Net debt; negative means net cash (AUD)

-221,809306,086-2,202,933

Total equity (AUD)

-168,321-833,1701,229,900

Issued capital (AUD)

14,628,11615,864,77918,968,387

Accumulated losses (AUD)

-16,815,150-19,059,413-20,987,829

Balance Sheet (AUD) and Per-Share Data

Metric (FY2026 report only)FY2025FY2026

Total assets (AUD)

1,021,8813,336,487

Total current assets (AUD)

835,9673,241,855

Trade and other receivables (AUD)

137,322290,781

Inventories (AUD)

207,308147,554

Total current liabilities (AUD)

1,784,9742,061,392

Contract liabilities / deferred revenue (AUD)

579,537681,697

Total liabilities (AUD)

1,855,0512,106,587

Working capital (AUD)

-949,0071,180,463

Goodwill and intangibles (AUD)

00

Net tangible assets per share (AUD cents)

-0.170.17

Cash Flow (AUD)

MetricFY2025FY2026

Receipts from customers (AUD)

989,4952,121,281

Payments to suppliers and employees (AUD)

-3,233,719-3,838,770

Government R&D grants received (AUD)

619,528610,680

Net interest paid (AUD)

-42,197-77,327

Operating cash flow (AUD)

-1,666,893-1,184,136

Capex: plant and equipment (AUD)

-7,094-3,814

Free cash flow (AUD)

-1,673,987-1,187,950

Net proceeds from share issues incl. options (AUD)

1,453,9713,816,640

Net borrowings (AUD)

-129,463-230,114

Lease repayments (AUD)

-74,187-81,353

Dividends paid (AUD)

00

Share buybacks (AUD)

00

Net change in cash (AUD)

-423,6662,317,223

Returns & Leverage Ratios (%) and Financial Ratios (x)

RatioFY2025FY2026Note

ROE (%)

n/m

n/m

Equity negative in FY2025; average equity near zero in FY2026

ROA on year-end assets (%)

-219.6-62.9

Derived

ROIC

n/m

n/m

Negative NOPAT; minimal invested capital

Current ratio (x)

0.471.57

Derived

Debt / equity (x)

n/m

0.43

Debt including leases

Net debt / EBITDA (x)

n/m

n/m

Net cash in FY2026; negative EBITDA

Interest coverage (x)

n/m

n/m

Negative EBIT

Asset turnover on year-end assets (x)

0.940.61

Derived; FY2026 lower because of the cash build

Receivable days

3752

Trade receivables (net) / sales x 365, derived

Inventory days

19661

Inventory / hardware expense x 365, derived

Payable days

11033

Trade payables / hardware expense x 365, derived

Cash conversion cycle (days)

12380

Derived; excludes the benefit of customer prepayments (contract liabilities)

Revenue by Region (AUD) and Revenue by Region (%)

RegionFY2025FY2026

Australia revenue (AUD)

956,7402,041,828

International revenue (AUD)

00

Australia share of revenue (%)

100100

State / Territory Details

State / TerritoryCustomer and sitesStatus (latest)

Victoria

mecwacare: Trescowthick Centre (Prahran, 60 beds), Allenvale, Caldwell Manor, Park Hill (4 sites, 223 beds live at 30 June 2026); 22 facilities in total under the MSA

Rolling out; 10 sites targeted by end of 2026

New South Wales

Hardi Aged Care: Manly Vale (100 beds), Blacktown (48 beds plus 84-bed expansion), Wyoming (63 beds), Seven Hills (104 beds) live; 2 more sites by end of 2026; about 580 beds across 6 sites

Rolling out; nurse call being added

New South Wales / ACT

Warrigal Care: 65 villas at a new retirement development; potential across 10 villages (~700 residents)

Implementation

Western Australia

WACHS: Koolberrin Lodge, Narembeen (regional)

Ongoing subscription

Share Price

MetricFY2020FY2021FY2022FY2023FY2024FY2025FY2026

Share price at 30 June (AUD)

0.3150.180.040.0120.0140.010.02

Performance Window Details

Performance window (to FY2026 close, A$0.02)Approx. returnCaveat

1 year

about +100%

FY2025 base is rounded to A$0.01; the true figure may differ materially

3 years

about +67%

Base A$0.012

5 years

about −89%

Base A$0.18

Since IPO

about −90%

Base A$0.20

Valuation Multiples

MultipleAt A$0.020At A$0.026

Market cap (AUD Mn)

14.318.6

Enterprise value, mcap minus net cash of A$2.20M (AUD Mn)

12.116.4

EV / Sales FY2026 (x)

5.98.0

P/e Details

P/En/m (loss)n/m (loss)

EV / EBITDA

n/m (negative)

n/m (negative)

P/B (x)

11.615.1

Capital Markets

ItemStatus

Analyst consensus

Not available. Simply Wall St lists one covering analyst but no submitted estimates

Dividend history

No dividends ever paid; none declared for FY2026 or FY2025

Dividend policy

No formal policy; losses and accumulated deficits preclude dividends

Buyback authorisations

None; no current on-market buyback (FY2026 Note 22)

Credit ratings (Moody's / S&P / Fitch)

Not rated

Debt maturity profile

All interest-bearing debt (A$497,640 at a 15% fixed rate) matures within 1 year; repaid from the FY2026 R&D refund

Options on issue

154,249,999 (exercise prices A$0.02–A$0.05; expiries May 2027 – May 2029)

Performance rights on issue

88,700,000

Trading liquidity

Low; micro-cap with large daily percentage swings

Analyst Conclusions

Management guidance

No quantitative revenue or earnings guidance has been issued. Operational targets:

  • 10 mecwacare sites live by the end of calendar 2026.

  • Remaining two Hardi sites live by the end of calendar 2026.

  • Hardi nurse call rollout across four more sites.

  • Warrigal implementation.

  • Full mecwacare rollout by FY2028.

  • CEO incentive hurdles of 700, 2,000 and 4,000 contracted revenue-generating beds by June 2027, 2028 and 2029.

Consensus

Not available.

Bull case

  1. The contracted backlog converts into visible revenue. Disclosed TCV of about A$12.3M (mecwacare ~A$8.8M, Hardi ~A$3.27M including the expansion, Warrigal ~A$0.2M) is about six times FY2026 sales revenue. If it is delivered on schedule through FY2028, it supports sustained growth and a rising recurring base.

  2. Operating leverage is real. Revenue doubled in FY2026 while staff costs fell and the EBITDA loss narrowed. The positive June-quarter operating cash flow shows the model can cover costs during heavy deployment periods.

  3. Nurse call broadens the opportunity. Hardi adopting nurse call across all six sites, and the explicit ability to replace legacy systems, can raise revenue per bed and make InteliCare an attractive bolt-on for consolidators in the sector.

Bear case

  1. Lumpy hardware revenue hides a weak recurring base. SaaS was only A$196,799 in FY2026, about 5% of annual cash operating payments. Once deployment bursts end, cash flow could quickly turn negative again.

  2. Dilution is relentless. Shares rose from 292M to 715M in two years, with about 243M more options and rights outstanding. Even successful execution may not lift per-share value much if more raisings follow.

  3. Concentration and execution risk. One customer (mecwacare) dominates near-term receipts. Delays, leadership changes at the customer, or incumbent competition (Austco at about 46 times the revenue) could derail the growth path, as happened in FY2023–FY2024.

Catalysts and monitorables (next 12 months)

Catalyst / monitorableExpected timing
September 2026 quarter 4C: whether positive operating cash flow continuesLate Oct 2026
FY2026 Annual Report: top-20 holders and governance disclosuresLate Oct 2026
AGM: incentive grants and board renewalNov 2026
mecwacare: 10 sites liveDec 2026
Hardi: final 2 sites plus nurse call rolloutDec 2026
Receipt of the FY2026 R&D refund and repayment of the 15% facilityH2 CY2026
H1 FY2027 results: revenue run-rate and SaaS growthFeb 2027
New contract signings (e.g. Bolton Clarke conversion, Warrigal expansion, new RAC operators)Ongoing
Progress toward 700 contracted bedsJun 2027
Any further capital raisingOngoing

Analyst verdict

InteliCare reached a genuine operational turning point in FY2026. After six years of pilots and sub-A$1M revenue, it signed a contract with mecwacare worth about four times its annual revenue. Its anchor customers are expanding their deployments: Hardi added beds and nurse call, and Warrigal opened a new vertical. The company produced evidence that resonates with aged care operators facing labour shortages and a tougher regulatory regime: falls detection with no recorded errors during the evaluation, and overnight welfare checks reduced from 55 residents to 4. The balance sheet moved from net liabilities to net cash, and the June quarter delivered the first positive operating cash flow since listing.

The quality of that inflection is still unproven. Ninety per cent of revenue is one-off hardware. Recurring SaaS revenue is around A$0.2M a year, and the cost base is roughly A$4M. The positive quarter came from a burst of mecwacare deployments, not from recurring revenue covering costs. Shareholders have been diluted about 2.4 times in two years, and roughly a third more potential shares sit in options and rights, many priced near the current share price. Governance is thin, with a three-person board, related-party service payments and performance rights held by non-executive directors. InteliCare is also entering nurse call, a category where a well-capitalised ASX incumbent is consolidating the Australian market.

On balance, ICR is a high-risk, binary-leaning execution story. The investment case depends on whether bed-count milestones (700 by June 2027) and SaaS growth arrive before the next capital raising. If they do, the current valuation of about 6–8 times trailing EV/Sales may compress quickly as recurring revenue builds, and strategic interest from consolidators becomes plausible. If deployments slip, the company's history of revenue stalls and dilution suggests downside. Investors should treat the September and December 2026 quarterly cash flow reports, rather than contract announcements, as the decisive evidence.


APPENDIX: SOURCES

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Executive Leadership Team

NameTitleTenurePrior rolesFY2026 total remuneration (AUD)

Angus Cameron

Chief Executive Officer

Since 16 Mar 2026

30+ years across aged care, health and technology in Australia, Asia-Pacific and the US; senior roles at Philips Healthcare (digital transformation, smart hospital strategy, health system partnerships)

164,222 (part year: salary 94,027; super 11,283; equity 58,912)

Mike Tappenden

Chief Technology Officer; co-founder

Service agreement since 20 Dec 2019

Co-founder; relevant interest in Forward Logic Pty Ltd

310,677 (salary 232,875; super 27,945; equity 49,857)

Neil Hackett

Company Secretary

Board member until 15 Sep 2022; company secretary since then

——

Daniel Pilbrow (former)

CEO

18 Jul 2022 – 10 Oct 2025

Silver Chain Group (Executive Director NSW, national M&A); also described as former Chief Strategy Officer at Opal HealthCare and with AMP Capital's social care division; trained physiotherapist

184,871 (part year)

“—” = not publicly disclosed.

Board of Directors

NameRoleAppointedBackgroundSharesPerf. rightsOptionsFY2026 total (AUD)

Dr Neale Fong

Non-Executive Chairman

21 Apr 2022 (initially Executive Chair)

Medical practitioner, 35+ years in health leadership; CEO and Executive Director of Bethesda Health Care; former Director General of WA Health; former CEO of St John of God Subiaco; former NED of Little Green Pharma (to June 2026)

018,500,0003,000,000165,227

Greg Leach

Non-Executive Director; co-founder

Founder

30+ years in ICT; co-founder and former CTO of Empired Ltd; co-founder of Frontline Services (now Forward Logic), BigRedSky; CEO of Blockhead Technologies; B.Bus (Information Processing)

46,046,01912,400,0004,666,66790,686

Tim Chapman

Non-Executive Director (Interim Executive Director Oct 2025 – Mar 2026)

25 Sep 2024

25+ years in corporate finance (IPOs, placements, M&A) focused on small-cap healthcare; founder of Clarity Capital Advisors; Chairman of HeraMED (ASX: HMD)

1,335,18112,000,00013,253,95490,339

Board & Management Changes

DateChangeContext

25 Sep 2024

Cam Ansell leaves the board; Tim Chapman joins

Board renewal toward capital markets expertise

Aug 2025

Pilbrow resignation announced

Left for a senior role at a large aged care provider

10 Oct 2025

Pilbrow departs; Chapman becomes Interim Executive Director with Tappenden

Leadership gap during the mecwacare pilot

16 Mar 2026

Angus Cameron appointed CEO

Coincided with the mecwacare MSA

Major Shareholders

HolderSharesStakeBasis / dateSource

Greg Leach (director and founder)

46,046,019

~6.44%

Of 714.75M shares, 30 Jun 2026

FY2026 Remuneration Report

Christopher Weed

38,300,000 acquired

~5–6% (derived; share count at time of purchase not confirmed)

On-market purchase about A$841k, 14 Nov 2025

Simply Wall St

Citicorp Nominees Pty Ltd

30,936,1456.35%

On ~487M shares (FY2025 annual report top 20)

Market Index

Carl Charalambous (and Chara Brothers)

27,727,374 at the Aug 2024 notice; further purchases late 2024

5.70% at notice

Substantial holder notice, 30 Aug 2024

Market Index; Simply Wall St

Ratdog Pty Ltd

20,053,8394.12%

FY2025 top 20

Market Index

Altor Capital Management

20,422,099

9.72% at the time

Notice dated 23 Oct 2023 (since heavily diluted)

Market Index

Tim Chapman (director)

1,335,181

~0.19%

30 Jun 2026

FY2026 Remuneration Report

KMP total direct shareholding

47,381,200

~6.63%

30 Jun 2026

FY2026 Remuneration Report

Competitive Landscape

Key Competitors

#CompetitorCategory overlapListingPositioning vs InteliCare
1

Austco Healthcare

Nurse call and clinical communications (core overlap since InteliCare's nurse call launch)

ASX: AHC

Incumbent with scale: FY2026 revenue A$94.2M, 5,000+ facilities in 60+ countries

2

Ascom

Nurse call and clinical workflow, aged care and hospitals

SIX: ASCN

—
3

Baxter (Hillrom / Voalte)

Nurse call and care communications

NYSE: BAX

—
4

Tunstall

Telecare, nurse call, community alarms

Private

Large legacy telecare provider; figures not disclosed

5

SafelyYou

AI video-based falls detection in senior living

Private (US)

Camera-based approach versus InteliCare's sensor-based approach

6

Vayyar

Radar-based contactless falls detection

Private (Israel)

Privacy-preserving sensing competitor

7

Kepler Vision Technologies

Computer-vision night monitoring and falls

Private (Netherlands)

Overnight monitoring competitor

8

Nobi

Smart lamp with falls detection

Private (Belgium)

Ambient device competitor

9

Electronic Caregiver

Remote monitoring and virtual care

Private (US)

Home monitoring overlap

10

Alcidion

Clinical informatics and smart hospital software

ASX: ALC

—
11

Aged care management system vendors (e.g. AlayaCare and others)

Care management and workflow

Mostly private

Integration partners or substitutes for dashboard features

Peer Comparison FY2026

Metric (FY2026, AUD)InteliCare (ICR)Austco Healthcare (AHC)

Revenue

A$2.04M

A$94.2M

Revenue growth

+113.4%+15.8%

EBITDA margin

−90.4%

~15.8% (EBITDA A$14.9M)

NPAT

−A$2.10M

A$9.0M

R&D intensity

Not disclosed (development expense 14.6% of revenue)

—

Cash

A$2.73M

A$16.3M (no material borrowings)

Company Snapshot

2016

Founded

Leederville, Australia

Headquarters

SWOT Analysis

Strengths

  • Anchor contract scale. The mecwacare MSA (~A$8.8M TCV over 5 years, 22 facilities) is about 4.3 times FY2026 sales revenue (FY2026 Directors' Report).
  • Proven clinical outcomes. At Trescowthick, all 11 jointly agreed success criteria were met or exceeded, and falls detection was 100% accurate with no false or missed falls (FY2026 Directors' Report).
  • Productivity evidence. Residents needing three-hourly overnight checks fell from 55 to 4 (FY2026 Directors' Report).
  • Upsell traction. Hardi expanded by +A$371k (+13% TCV) and adopted nurse call across all 6 facilities (ASX, 28 July 2026).
  • Operating leverage emerging. FY2026 sales revenue rose 113.4% while staff expense fell 7.1%, and the EBITDA loss improved by A$220,727 (FY2026 Financial Report).
  • First positive operating cash quarter. +A$384k in the June 2026 quarter (Appendix 4C, 29 July 2026).
  • Clean audit. Unmodified opinion for FY2026, with no audit disputes or qualifications (Appendix 4E).

Weaknesses

  • Persistent losses. Six consecutive annual losses of A$2.1M–A$3.9M (FY2022–FY2026); accumulated losses of A$20.99M (FY2026 Note 25).
  • Hardware-heavy mix. Hardware made up 90.4% of FY2026 sales revenue; SaaS was only A$196,799 (FY2026 Note 5).
  • Customer concentration. mecwacare produced about A$1.5M of the A$1.806M June-quarter receipts (Kalkine summary of the June quarter update).
  • Thin governance bench. A three-person board with related-party payments to entities linked to two directors (A$333,093 in FY2026) and performance rights held by the chair (FY2026 Remuneration Report).
  • Expensive debt. The R&D advance carries 15% interest; finance costs rose 80% to A$151,297 (FY2026 Notes 7 and 20).
  • Administrative lapse. Option expiries were not notified to the ASX on time, as identified at the July 2026 reconciliation (Kalkine, 23 July 2026).

Opportunities

  • Bed-count ramp. CEO hurdles target 700, 2,000 and 4,000 contracted beds by FY2027, FY2028 and FY2029 (FY2026 Remuneration Report).
  • Nurse call displacement. InteliCare can replace parts of legacy nurse call systems, opening a larger wallet share per facility (ASX, 28 July 2026; StockWireX, March 2026).
  • Retirement living. Warrigal's 10 villages and ~700 residents give a pathway beyond the first 65 villas (FY2026 Directors' Report).
  • At-home care. The mecwacare partnership explicitly includes exploring at-home and emerging service models (FY2026 Directors' Report).
  • Regulatory pull. Alignment with the new Aged Care Act and Quality Standards (FY2026 Directors' Report).
  • Pipeline conversion. Bolton Clarke trials (MoU November 2023) and the WACHS extension options.

Threats

  • Incumbent scale. Austco: A$94.2M revenue, A$16.3M cash, an active acquisition strategy, and 5,000+ facilities (FilingReader / SmallCaps, August 2026).
  • Dilution. Shares on issue rose 145% in two years (292.1M at 1 July 2024 to 714.8M at 30 June 2026), with a further ~243M options and rights outstanding (FY2026 Notes 22 and 24).
  • Funding dependence. FY2026 operating cash outflow was still A$1.18M; equity raisings were needed in September 2025 and May 2026.
  • Deployment execution. Revenue depends on hitting site milestones (10 mecwacare sites by December 2026); delays would hit hardware billings.
  • Key person risk. Two CEO changes in four years (Waller in 2022, Pilbrow in 2025).
  • Technology substitution. Radar and computer-vision falls detection competitors (Vayyar, SafelyYou, Kepler Vision).

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
FY2025 (H2)Hardi third and fourth facility deployments begin; initial hardware revenue of A$239kBuilds toward the A$400k per year SaaS run-rate across 6 sites
FY2025mecwacare full-facility pilot at Trescowthick Centre (60 beds)Pilot assessed against 11 jointly agreed criteria
Jul 2025A$400k R&D-secured loan with conversion featureBridge funding at 15% interest
Aug 2025CEO Daniel Pilbrow announces resignationLeadership risk during the critical pilot
29 Aug 2025FY2025 preliminary results: loss A$2.24MNet liabilities of A$833k at year end
Sep 2025~A$2.0M two-tranche placement; convertible facility terminatedBalance sheet repair
10 Oct 2025Pilbrow departs; Chapman becomes Interim Executive DirectorInterim leadership
27 Oct 2025FY2025 Annual Report releasedStatutory filing
29 Oct 202512M performance rights granted to CTO TappendenRetention
14 Nov 2025Christopher Weed buys 38.3M shares (about A$841k)Significant new individual holder
19 Nov 2025AGM; all resolutions pass; 15M director performance rights approvedGovernance
Late 2025Seven Hills becomes the fourth Hardi facilityFootprint growth
9 Jan 2026Proposed issue of securities (performance rights tranche)Incentive grants
30 Jan 2026December quarter update: mecwacare talks progressing; nurse call integration features extendedPipeline signal
26–27 Feb 2026H1 FY2026: revenue A$489,707 (−2.3%); loss A$1.37M (+77.1%)Weak first half before the inflection
Mar 2026Five-year mecwacare MSA, ~A$8.8M TCVTransformational contract (about 4.3 times FY2026 revenue)
16 Mar 2026Angus Cameron appointed CEOLeadership filled
25–26 Mar 2026Presentation at NWR Virtual Healthcare Conference (Tim Chapman)Investor outreach
27 Mar 2026Proposed issue of securities (CEO performance rights)Incentive
21 Apr 2026Investor presentation (lodged on ASX 16 Jun 2026)Strategy articulation
23 Apr 2026Warrigal retirement living deployment announcedNew vertical
30 Apr 2026March quarter reportConfirms the MSA, CEO hire and Trescowthick results
7 May 2026A$2.05M placement at A$0.022 to support scale-up (after a trading halt)Funding for the rollout
19–22 May 2026Quotation of placement shares; cleansing noticeCompletion
Jun 2026Four mecwacare sites (223 beds) liveOn schedule
23 Jul 2026Issued capital reconciliation; overdue Appendix 3H filed for expired optionsMinor compliance lapse
28 Jul 2026Hardi expansion: +84 beds and nurse call across 6 facilities; +A$371k (+13% TCV)Upsell proof point
29 Jul 2026June quarter: operating cash flow +A$384k; receipts A$1.806MFirst positive quarter since listing
26–27 Aug 2026FY2026 Appendix 4E: revenue A$2.04M (+113%); loss A$2.10M (−6.5%); unmodified auditResults
27 Aug 2026Austco Healthcare (nurse call peer) reports FY2026 revenue of A$94.2MCompetitive context
Expected late Oct 2026FY2026 Annual Report and September quarter 4C (not yet released at the dossier date)Upcoming
Expected Nov 20262026 AGMUpcoming

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

8 charts
Income Statement (AUD): Total revenue and income to Staff expense: Total revenue and income rose from AUD 1,584,114 in FY2025 to AUD 2,661,183 in FY2026.
Intelicare Holdings Limited — Income Statement (AUD): Total revenue and income to Staff expense
Series (AUD)FY2025FY2026
Total revenue and income1,584,1142,661,183
Other income incl. R&D grants and interest627,374619,355
Hardware expense-385,173-882,227
gross profit: sales minus hardware expense571,5671,159,601
Development expense-310,530-297,791
Marketing and advertising-7,622-34,042
Staff expense-1,660,699-1,543,224

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.